Ampio Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards
By PR Newswire
ENGLEWOOD, Colo., Dec. 27, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") today announced that it has received notification from The NYSE American LLC ("NYSE American") stating that the Company has regained compliance with the NYSE American's continued listing standards. Specifically, the Company has resolved the continued listing deficiency with respect to its low selling price as described in Section 1003(f)(v) of the NYSE American Company Guide.
In the notification, the NYSE American informed the Company that as of December 27, 2022, the below compliance (".BS") indicator will no longer be disseminated and the Company has been removed from the NYSE American noncompliant issuers on the NYSE American's website.
About Ampio Pharmaceuticals, Inc.
Ampio Pharmaceuticals, Inc. is a pre-revenue stage biopharmaceutical company that is engaged with the early development of AR-300, a synthetic pre-clinical stage development asset which has been designed to leverage the key attributes of Ampion. The Company is currently conducting preclinical studies on AR-300 and engaged in a strategic alternatives process that could include outbound strategic in-licensing / acquisition efforts with a key focus on late-stage development assets / programs which would strengthen its existing pipeline.
For more information, contact:
Ampio Pharmaceuticals, Inc.
Chief Executive Officer
SOURCE Ampio Pharmaceuticals, Inc.Head to the TechDogs homepage to find the latest tech content infused with drama and entertainment. We've got Articles, White Papers, Case Studies, Reports, Videos and Events – the complete lot to help you Know Your World of Technology.
First published on Wed, Dec 28, 2022
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs’ members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs’ Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. All information / content found on TechDogs’ site may not necessarily be reviewed by individuals with the expertise to validate its completeness, accuracy and reliability.
Join The Discussion